Loading...
Market
Will GSK complete Phase 3 trials for CMG1A46 by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from GSK or clinical trial registries
Story
British GSK Acquires Experimental Lupus Drug from Chimagen Biosciences for Up to $850 Million
Oct 29, 2024, 12:27 PM
British drugmaker GSK has entered into an agreement to acquire CMG1A46, an experimental drug from Chinese biotech firm Chimagen Biosciences, for up to $850 million. This acquisition includes a $300 million upfront payment and aims to expand GSK's pipeline of potential treatments for lupus. The drug, CMG1A46, is a clinical-stage dual CD19 and CD20-targeted T cell-engager, which is expected to enhance GSK's immunology portfolio.
View original story
Similar markets
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial discontinued • 25%
Positive • 33%
Neutral • 33%
Negative • 33%
